Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 777 Old Saw Mill River Road TARRYTOWN NY 10591 |
Tel: | N/A |
Website: | https://www.regeneron.com |
IR: | See website |
Key People | ||
Leonard S. Schleifer Co-Chairman of the Board, President, Chief Executive Officer, Founder | George D. Yancopoulos Co-Chairman of the Board, President, Chief Scientific Officer | Christopher R. Fenimore Chief Financial Officer, Senior Vice President - Finance |
Joseph J. LaRosa Executive Vice President, General Counsel, Secretary | Daniel P. Van Plew Executive Vice President, General Manager - Industrial Operations and Product Supply | Marion E. McCourt Executive Vice President - Commercial |
Andrew J. Murphy Executive Vice President - Research | Neil Stahl Executive Vice President - Research and Development | Jason Pitofsky Vice President, Controller |
Business Overview |
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Regeneron Pharmaceuticals Inc revenues increased 8% to $13.12B. Net income decreased 9% to $3.95B. Revenues reflect Sanofi segment increase of 33% to $3.8B, Libtay-ROW segment increase from $73M to $324.3M. Net income was offset by Selling, general increase of 25% to $2.32B (expense), Research and development increase of 21% to $2.41B (expense). |
Employees: | 13,450 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $97,921M as of Dec 31, 2023 |
Annual revenue (TTM): | $13,117M as of Dec 31, 2023 |
EBITDA (TTM): | $4,654M as of Dec 31, 2023 |
Net annual income (TTM): | $3,954M as of Dec 31, 2023 |
Free cash flow (TTM): | $3,668M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 109,761,896 as of Jan 25, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |